



## Biograstim

### Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
IA/0031/G	<p>This was an application for a group of variations.</p> <p>B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material</p> <p>B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a</p>	22/11/2013	n/a		

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>Member State - Excipient/AS starting material</p> <p>B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material</p> <p>B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material</p> <p>B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material</p>				
IB/0029	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	30/10/2013		SmPC and PL	Update of sections 4.4 and 4.8 of the SmPC to include a new adverse reaction, capillary leak syndrome, and a related warning following the same update for the originator. The PL is updated accordingly.
T/0028	Transfer of Marketing Authorisation	16/08/2013	09/10/2013		
R/0025	Renewal of the marketing authorisation.	30/05/2013	25/07/2013	SmPC, Annex II, Labelling and PL	
IA/0027/G	<p>This was an application for a group of variations.</p> <p>B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation</p> <p>B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished</p>	11/07/2013	n/a		

	product - Deletion of a non-significant in-process test				
IA/0026	B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits	11/04/2013	n/a		
IB/0024/G	This was an application for a group of variations.  B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation  B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits	18/01/2013	n/a		
II/0022/G	This was an application for a group of variations.  To introduce a new site for WCB manufacture. To introduce a new WCB lot and some modifications to the manufacturing process of the WCB (change in scale, harvesting time and freezing volume).  B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product  B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol	15/11/2012	n/a		

IB/0023	C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH	24/10/2012	n/a	SmPC, Annex II, Labelling and PL	
IB/0020/G	This was an application for a group of variations.  B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure  B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	21/09/2012	n/a		
IA/0021	A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)	11/09/2012	n/a		
II/0019	Replacement of the peptide mapping method.  B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS	19/07/2012	n/a		
IB/0017	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	10/05/2012	n/a		

IA/0015/G	<p>This was an application for a group of variations.</p> <p>B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method</p> <p>B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p>	14/03/2012	n/a		
IAIN/0016	A.1 - Administrative change - Change in the name and/or address of the MAH	07/03/2012	n/a	SmPC, Labelling and PL	
IB/0014	B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)	08/12/2011	n/a		
IA/0013/G	<p>This was an application for a group of variations.</p> <p>B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits</p> <p>B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits</p> <p>B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction</p>	25/10/2011	n/a		
II/0012/G	This was an application for a group of variations.	20/10/2011	20/10/2011		

	<p>Introduction of additional sterile filtration steps in the manufacturing process for the active substance. In addition, new in-process tests and limits are introduced.</p> <p>B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol</p> <p>B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits</p>				
II/0010	<p>Introduction of a new Pharmacovigilance System (TEVA DDPS Version 10), including a new Qualified person for Pharmacovigilance.</p> <p>Annex II.B has also been updated with the latest wording as per October 2010 CHMP procedural announcement.</p> <p>C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH</p>	23/06/2011	05/08/2011	Annex II	<p>The MAH has introduced a new pharmacovigilance system used by TEVA Pharmaceutical Industries Ltd., which will be applied for the product Biograstim. The detailed description of this pharmacovigilance system includes information pertaining to the qualified person responsible for pharmacovigilance, the global structure of the pharmacovigilance organisation, company procedures relating to pharmacovigilance activities, global safety databases, links with other organisations, training and the quality management system. The MAH has also taken the opportunity to update Annex II.B with the latest wording as per October 2010 CHMP procedural announcement.</p>
IB/0011/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test</p>	20/07/2011	n/a		

	procedure				
IB/0009/G	<p>This was an application for a group of variations.</p> <p>C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH</p>	21/02/2011	n/a	SmPC and PL	<p>To implement changes requested in the PSUR 3 Assessment Report (dated 06 August 2010), as well as to bring the Product Information in line with the SmPC of the reference product (Neupogen). Minor linguistic amendments are introduced in the Package Leaflet for the following languages: CS, DA, ET, ES, FI, FR, HU, IT, NL, PL .</p> <p>In addition, the MAH amended the European Medicines Agency web address in section 10 of the SmPC.</p>
IB/0008	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	27/08/2010	n/a		
II/0005	<p>Addition of an alternative site for manufacture (formulation, filling) of drug product.</p> <p>B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products.</p>	24/06/2010	06/07/2010		
IB/0006	<p>To change a test procedure for the active substance</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for</p>	20/05/2010	n/a		

	the AS or a starting material/intermediate				
IB/0007	To change a test procedure for the finished product  B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	20/05/2010	n/a		
IA/0004	B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information	05/03/2010	n/a	PL	
II/0001	Extension of the finished product shelf-life from 24 to 30 months.  Change(s) to shelf-life or storage conditions	19/11/2009	23/12/2009	SmPC, Annex II, Labelling and PL	
IA/0002	IA_28_Change in any part of primary packaging material not in contact with finished product	06/10/2009	06/10/2009	SmPC, Labelling and PL	
IA/0003	IA_28_Change in any part of primary packaging material not in contact with finished product	06/10/2009	06/10/2009	SmPC, Labelling and PL	

Medicinal product no longer authorised